News: $HZNP Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases FullâYear 2019 Net Sales and Adjusted EBITDA Guidance
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million; KRYSTEXXA ® Second-Quar...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.